Cellular ependymoma
diseaseOn this page
Summary
Cellular ependymoma (MONDO:0003470) is a disease and 1 clinical trial. Top therapeutic interventions include 2-mercaptoethanesulfonic acid and vincristine. A subtype of ependymoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 1
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | cellular ependymoma |
| Mondo ID | MONDO:0003470 |
| DOID | DOID:5500 |
| NCIT | C4713 |
| UMLS | C1384403 |
| MedGen | 235137 |
| GARD | 0023517 |
| Is cancer (heuristic) | no |
Disease family
This is a subtype of ependymoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › nervous system neoplasm › neuroepithelial neoplasm › glioma › ependymal tumor › ependymoma › cellular ependymoma
Related subtypes (7): spinal cord ependymoma, tanycytic ependymoma, papillary ependymoma, clear cell ependymoma, brain stem ependymoma, childhood ependymoma, low grade ependymoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 1.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01096368 | PHASE3 | COMPLETED | Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| 2-MERCAPTOETHANESULFONIC ACID | 4 | 2 |
| VINCRISTINE | 4 | 1 |